Med-Lab, short for ‘medical laboratory,’ has created confusion around its offering and limited its capabilities for some time. Their new name, Centella, is inspired by the Spanish word for “spark” and represents their aspiration to drive innovation and further push boundaries in healthcare technology. The new logo represents a team huddle, demonstrating the need for collaboration, teamwork, and communication to meet this aspiration.

For over 60 years, Med-Lab has had a reputation as the most trusted partner in medical imaging. They are ubiquitous in virtually every hospital system in South Florida. As a Siemens Healthineers Advanced Partner, they are proud to introduce world-class OEM technology into its local community.

CEO Gonzalo Diaz III said, “We focus on building trusted partnerships, and when our customers asked us for more, we accepted the challenge.” Diaz continued, “We work together with our customers to push existing boundaries for the benefit of our community.”

After conversations with customers, they saw the opportunity to do more, expanding their service offerings to Healthcare Technology Solutions, a service-based offering for the maintenance and safe use of all health technology and medical equipment within a clinical facility.

After successfully piloting the offering with Broward Health, the Centella team is excited to bring it to market.

Diaz notes, “Since 1967, despite social unrest, economic downturns, and a global pandemic, Med-Lab has delivered technological solutions with compassion and collaboration. This will never change.”

The post Med-Lab Announces New Name, Look & Business Expansion first appeared on AI-Tech Park.

Mytonomy Inc., a leader in cloud solutions for health education and engagement, announced today that the company is a proud participant of the American Academy of Orthopaedic Surgeons’ (AAOS) Patient-Reported Outcome Measures (PROMs) Vendor Program^[1]. The program is designed to offer a rich library of technology vendors and solutions to AAOS members and their orthopedic care teams, supporting them with the collection and analysis of patient outcomes data.

The Mytonomy Cloud for Healthcare platform streams orthopedic patient education video content and provides comprehensive guidance, supporting patients through the entire perioperative journey for joint replacement from initial shared decision-making and HOOS/KOOS assessment to post-operative rehabilitation and recovery at home.

“Joining the AAOS PROMs Vendor Program underscores how effective patient education strategies can enhance the collection of patient-reported outcomes,” said Mytonomy President and Co-Founder Vinay Bhargava. “With seamless integration with Epic and other EHR/CRM systems, healthcare systems will also benefit by supporting their Orthopedic Service Lines in scaling their patient volumes by reducing the need to hire additional nurse navigators, increasing efficiency.”

Mytonomy Cloud for Healthcare is designed to educate patients undergoing orthopedic surgery to help reduce delays in scheduling surgery, decrease length of stay, and improve surgical outcomes. The content supports patients in recovering at home instead of returning to the hospital and aims to increase overall patient satisfaction. Customer feedback to KLAS Research resulted in a category-leading score, showcasing Mytonomy’s expertise in the field.

“Mytonomy’s unique approach to patient education leverages its video consumption by patients to drive PROM survey completion,” added Vinay Ambekar, executive vice president of engineering and product, Mytonomy. “Our data shows that Medicare-eligible patients watch over 30 minutes of our expert content. More than half of the invited patients log in and watch our content. We are proud that leading health systems have digitized their pre-surgical orthopedic education classes, moving the experience onto the Mytonomy platform, saving time and resources for clinicians.”

“Finding the right technology vendor who can help ease the burden of collecting patient-reported outcome data is vital, but often complicated,” said Kurt P. Spindler, MD, FAAOS, AAOS PROMs workgroup chair. “We are pleased to welcome Mytonomy into AAOS’ circle of featured PROMs vendors and look forward to further assisting and educating AAOS members with the PROMs implementation process.”

The post Mytonomy Joins the AAOS’ PROMs Vendor Program first appeared on AI-Tech Park.

In the last decade, the use of high deductible health plans (HDHP) with HSA accounts has more than doubled (link) and more than quadrupled for those without HSA accounts. These HDHP plans can have out of pocket maximums of $6,900 (individual) or $13,800 (family), putting a much higher cost burden on the patient and shifting more of a practice’s outstanding receivables away from standard insurance payments. For the first time ever, patient receivables are now a larger portion of open A/R than insurance for many practices (link).

This shift means practices are increasingly faced with the added responsibility of educating patients on coverage and costs. Additionally, manual outreach for patient collections and bad debt creates more strain on practice resources. All of this presents challenges while trying to use inadequate, ineffective solutions.

Greenway Health Pay aims to alleviate confusion and frustrations for patients and practices by providing easy access to cost information, convenient payment methods and simple payment plans. Ready to use with both of our Greenway’s EHR platforms, this new suite of solutions includes on-demand payment options, flexible payment plans for pre-payment or existing balances, electronic statements, and balance information. Patients will be able to breeze through the process with the ability to have a saved payment method or “card on file.” Having the tools to provide upfront information and the means to accept payment at all stages of the visit allows practices to improve overall collections and streamline disparate A/R collections processes.

Greenway Health Pay will give patients visibility and access to electronic statements and up-to-date account balances. Patients will have access to multiple contactless payment options through text, email, online, card on file or their patient portal. Greenway Health Pay will provide peace of mind with secure payment options and simple setup of payment plans for upcoming expenses or outstanding balances.

“With the growing financial responsibility of patients as consumers, coupled with expectations for flexible payment options, the patient payment space presents tremendous opportunity for innovation”, said David Cohen, Chief Product and Technology Officer at Greenway Health. “We believe that combining convenience and flexibility with safety and security in a consumer-friendly package will also result in improved collections – and financial wellness – for both providers and their patients.”

Greenway Health is a leading health information technology service provider specializing in electronic health records with its flagship Intergy and Prime Suite products. Greenway and its award-winning solutions have been ranked highly in the Best in KLAS awards by KLAS Research, an independent research organization that assesses healthcare vendor performance through independent feedback from users. Additionally, Greenway Health’s revenue cycle solution, Greenway Revenue Services, was named the 2023 North American Customer Value Leadership Award in Frost & Sullivan’s Best Practices Award.

The post Greenway Health launched Greenway Health Pay powered by InstaMed first appeared on AI-Tech Park.

Avicenna.AI, a leading medical imaging AI company, has received Medical Device Regulation (MDR) certificate for five of its algorithms from certification body BSI Medical Devices. This development means the company’s product portfolio is fully compliant with the European Union’s MDR 2017/745, which is now mandatory for medical device companies that want to provide their solutions in Europe.

The MDR was introduced to update the EU’s regulations for medical devices, addressing safety issues and the recent emergence of AI tools and software as a medical device (SaMD), which did not exist when the old regulations were created. Ensuring MDR compliance is a critical component of obtaining and maintaining CE-mark status, which allows a device to be freely traded in the EU.

Compared to the previous Medical Device Directive (MDD), the MDR has a wider scope and more stringent requirements. It emphasizes clinical evaluation, post-market surveillance, device traceability, rigorous technical documentation, and risk management. These measures aim to enhance patient safety and ensure high standards for medical devices, including AI and software-based solutions.

Avicenna.AI’s products have been certified as Class IIb medical devices, which requires a high level of clinical validation. The certified products include the company’s suite of AI tools for neurovascular conditions, as well as its suite of algorithms for vascular conditions.

“Obtaining MDR certification is a significant milestone for Avicenna.AI,” said Stéphane Berger, Regulatory Manager at Avicenna.AI. “It demonstrates our commitment to meeting the highest standards of medical device safety and performance. This certification not only reinforces our dedication to compliance but also assures our customers of the quality and reliability of our AI product portfolio.”

The company’s MDR-certified AI tools include algorithms for intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), quantification of stroke severity (CINA-ASPECTS), aortic dissection (CINA-AD), pulmonary embolism (CINA-PE), and opportunistic cases of pulmonary embolism (CINA-iPE). All the products are also CE-marked and FDA-cleared.

“Crucially, despite the differences in SaMD regulatory requirements between authorities in the US and Europe, we are consistently achieving both FDA and CE mark clearance for our AI products,” added Berger.

All of Avicenna.AI’s AI tools are seamlessly integrated into radiologists’ clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Avicenna.AI secures MDR certification for medical imaging AI portfolio first appeared on AI-Tech Park.

Overwhelmed by administrative tasks, clinicians often have limited time for quality patient interactions. Stella tackles this challenge by automating processes and streamlining workflows. Clinical Copilot is built on four pillars of success:

• Data-Driven Accuracy: Stella leverages 150 years of research, 220 million+ relationships, and 16 million biomedical insights to support clinical decisions with robust data. Imagine having decades of knowledge at your fingertips to inform every patient interaction.
• Enhanced Efficacy: Leveraging best practices and real-time insights, Stella empowers clinicians to deliver the most effective care, significantly improving patient outcomes.
• Streamlined Efficiency: Effortless notes, smart automation, and smooth EHR integration. Free up valuable time for what matters most – patient care.
• Measurable ROI: Improved documentation, reduced administrative burdens, and increased patient satisfaction, lead to  increased ROI. Stella is an investment in the future of your practice.

Here’s how Stella Clinical Co-pilot delivers on these promises: 

• Effortless Note Generation: Generate accurate and concise clinical notes with ease. Stella can dictate your patient interactions, automatically capturing key details and generating comprehensive summaries.
• Individualized Intelligence: Grounded in extensive research, Stella transcends traditional reliance on only population-level data. Now, Stella delivers individualized insights, significantly enhancing and supporting precision in clinical decision-making.
• Personalized Recommendations: Leverage Stella’s vast knowledge base to provide tailored recommendations for each patient.

Beyond Efficiency, Stella Bolsters Clinical Decision-Making: 

Stella uses advanced graph neural networks to analyze medical data, uncovering complex relationships between symptoms, diagnoses, and treatments. This provides clinicians with real-time, personalized insights for better decision-making and improved patient outcomes.

“Stella Clinical Co-Pilot is set to revolutionize clinical note-taking and streamline administrative tasks for healthcare professionals. It offers advanced patient data management, automated note generation, and seamless integration capabilities, significantly reducing the administrative burden on clinicians and enhancing overall healthcare efficiency,” says Ritu Mehrotra, Founder and CEO at United We Care.  

United We Care remains dedicated to harnessing the power of AI to improve mental health and well-being globally. Learn more about Stella Clinical Co-pilot and how it can transform your practice atwww.unitedwecare.com

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post United We Care Unveils Stella, the Groundbreaking AI Clinical Co-pilot first appeared on AI-Tech Park.

Transforming cohort retrieval

Identifying patient cohorts is essential for clinical trials, retrospective studies, and other healthcare applications. Traditional methods relying on automated queries of structured data combined with manual curation are time-consuming and often yield low-quality results. Mendel’s AI offerings utilize a unique approach that couples a world-class clinical LLM trained to understand structured and unstructured text with a proprietary reasoning engine infused with medical knowledge reviewed by medical professionals to apply a clinician’s mind to complex and varied medical situations. This ability to apply clinical reasoning to ACR has been demonstrated to offer significant improvements over existing Retrieval-Augmented Generation (RAG) and LLM techniques.

“Our latest research at Mendel marks a significant milestone in the field of AI in general, and healthcare in particular,” said Wael Salloum, Cofounder and Chief Science Officer at Mendel. “We are the leader in clinical reasoning by coupling LLMs with our hypergraph reasoning, enhancing both the effectiveness and efficiency of patient cohort retrieval. This work is critical in paving the way for more robust and scalable clinical reasoning. This breakthrough underscores our commitment to advance the AI field to transform clinical research and improve patient outcomes.”

Key findings of the study include:

This research introduces two types of reasoning to the AI field:

1. Longitudinal Reasoning: Mendel’s neuro-symbolic architecture outperformed pure LLM approaches by efficiently handling the longitudinal nature of unstructured Electronic Medical Records (EMRs). As a patient’s record unfolds over time, the system reasons over the emerging facts, contrasting, rejecting, and consolidating them into a symbolic patient journey. Unlike LLM-only approaches, this approach processes a patient’s EMR just once, offline, to construct a journey that can be queried repeatedly at minimal cost.
2. Large-Scale Reasoning: Mendel’s integration of real-time hypergraph reasoning and a clinical LLM achieved higher Precision and Recall in cohort retrieval tasks. Unlike LLM-only solutions, which process the entire patient database for each query—making them infeasible for healthcare applications—Mendel’s approach maintains a fixed cost per query, regardless of the database size.

Benchmark and evaluation

Mendel’s research introduces a new benchmark task for ACR, featuring a comprehensive query dataset and an evaluation framework. The study compared the performance of Retrieval Augmented Generation (RAG) and LLM-based solutions and Mendel’s neuro-symbolic systems, providing a detailed analysis of their effectiveness and efficiency.

In the evaluation, Mendel had a 1.4K patient data set, and Mendel evaluated several embeddings and found Ada outperformed others. The evaluation report compares Ada with GPT-4 (RAG) to Mendel’s Neuro-symbolic System, Hypercube. F1 score is the key metric used to evaluate the accuracy of models, balancing both precision (how many of the results are relevant) and recall (how many relevant results were identified). This score provides a comprehensive measure of the model’s performance.

Below are the sample results of F1 scores:

1. Medium complexity with most queries (52)
2. Broad cohort size
3. Document count is greater than 74

Future implications

The findings underscore the transformative potential of Mendel’s Neuro-Symbolic AI system by combining LLMs with domain-specific knowledge embedded in hypergraphs. This approach enhances the accuracy and efficiency of cohort retrieval, facilitating more precise patient stratification and targeted interventions for new therapies. It also paves the way for broader applications in clinical research and patient care.

Mendel is offering a free “TryMe” demo to showcase the company’s Neuro-Symbolic AI system.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Mendel’s New Neuro-Symbolic AI Outperforms GPT-4 in Cohort Retrieval first appeared on AI-Tech Park.

QuantHealth, the leading AI-driven clinical trial design company, today announced a partnership with OMNY Health, the premier healthcare ecosystem for facilitating compliant cross-industry health data sharing. This collaboration aims to unlock novel insights from OMNY Health’s vast network of de-identified data, fostering new opportunities for clinical trials, evidence-based practice, and medical research for QuantHealth’s customers, which include four out of the five largest pharmaceutical companies globally.

By integrating diverse EHRs into organized, de-identified research data products, OMNY equips researchers and providers with comprehensive information to address disparities in clinical trials and close significant demographic information gaps in drug discovery and development. OMNY’s extensive data portfolio supports downstream analytic needs for life sciences innovation. The partnership with QuantHealth will unlock insights to accelerate life-changing innovation, further underscoring data as the power source for AI companies.

QuantHealth’s AI technology, trained on a dataset of 350 million patients, enhances clinical trial timelines, mitigates trial risks, and identifies sub-populations likely to respond to treatments. This collaboration will help QuantHealth’s pharmaceutical partners expedite drug development through simulated clinical trials informed by real-world evidence and predicted clinical trial outcomes, drug efficacy, and patient responses.

“Biotech is entering a vibrant part of life sciences history,” said Omri Matalon, VP Clinical Data Science and Head of R&D Operations. “This partnership with OMNY Health furthers QuantHealth’s commitment to quality data and access for our partners. “This diverse and highly organized, de-identified research and data will optimize our simulated clinical trials, enabling us to provide the highest quality insights to our life sciences partners and continue to revolutionize the research and development arena.”

This partnership represents OMNY Health’s focus on life sciences data and accelerating diverse participation in clinical trials, significantly enhancing its real-world data ecosystem, which supports compliant research AI company partnerships at scale. By facilitating secure and mutually beneficial data sharing, OMNY helps companies like QuantHealth simulate trials at scale and expedite, de-risk, and optimize drug development, to provide the world with effective medication expeditiously.

“Life sciences organizations and healthcare providers often face time and budget constraints that limit their ability to utilize their data effectively. By partnering with QuantHealth, we can break down these barriers and provide organized, on-demand, and data-driven answers to pressing clinical questions. This collaboration will accelerate drug development and optimize clinical trials, leading to improved therapeutic outcomes and enhanced patient care,” said Mitesh Rao, CEO, of OMNY Health. “Our mission is to free data from silos, enabling it to be shared, analyzed, and transformed into life-saving treatments and improved patient care.”

This collaboration follows QuantHealth’s recent strategic investment from Accenture Ventures and a leading CRO firm, bringing its Series A funding total to $17M. Founded in 2020, QuantHealth aims to help pharmaceutical companies advance and de-risk their programs by using AI to simulate clinical trials. The company’s technology predicts clinical trial outcomes, drug efficacy, and patient responses, delivering real-world evidence and enhancing clinical trial success.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post QuantHealth Taps OMNY Health to Improve AI Platform Dataset Structures first appeared on AI-Tech Park.

OMNY Health, the leading healthcare ecosystem known for facilitating compliant cross-industry data sharing launched its platform designed to power AI-driven health technology companies, further cementing the company’s commitment to democratizing healthcare data. QuantHealth and ArisGlobal are just two of OMNY’s newest partners to leverage this new platform to power their organizational AI-driven needs. OMNY Health’s data network uniquely addresses Generative AI’s need for large de-identified structured and unstructured electronic health record (EHR) data sets across diverse provider and patient populations, further underscoring the platform as delivering the data infrastructure and rails for provider organizations to collaborate and fuel the development and use of effective AI solutions for advancing healthcare.

“Our mission is to free data from silos, allowing it to be shared, analyzed, and morphed into life-saving treatments and better care for patients,” said Mitesh Rao, CEO, OMNY Health. “Life science organizations and providers often struggle with time and budget constraints that hinder their ability to learn from their data. Our work powering AI-driven platforms can unblock this process by partnering with AI developers with data and tools to accelerate breakthrough therapies and monitor new therapies for safety signals to ensure patient populations remain safe.”

Two of OMNY Health’s AI-driven partners being effectively powered by the platform’s data to foster new opportunities for advancing healthcare include QuantHealth, the leading AI-driven clinical trial design company, and ArisGlobal, a technology company at the forefront of life sciences and creator of LifeSphere®.

QuantHealth’s AI technology, trained on a dataset of 350 million patients, enhances clinical trial timelines, mitigates trial risks, and identifies populations likely to respond to treatments. OMNY’s collaboration will help QuantHealth’s pharmaceutical partners expedite drug development through simulated clinical trials, utilizing real-world evidence to predict clinical trial outcomes, drug efficacy, and patient responses.

“Biotech is entering a vibrant part of life sciences history,” said Omri Matalon, VP Clinical Data Science and Head of R&D Operations at QuantHealth. “This partnership furthers our commitment to quality data and access for our life sciences partners. By integrating diverse EHRs into organized, de-identified research data products, we can address disparities in clinical trials and close significant demographic information gaps in drug discovery and development.”

OMNY’s partnership with ArisGlobal, a leader in pharmacovigilance, safety monitoring, and reporting systems, will transform safety signal validation and pave the way for comprehensive, proactive signal detection.

“Up to 95% of adverse event cases go unreported today, while processing ICSRs can be time consuming, and analysis of medical literature and online forums is slow and inefficient,” said Ann-Marie Orange, CIO and Global Head of R&D at ArisGlobal. “Combining LifeSphere products with comprehensive real-time RWD addresses these challenges head-on. By leveraging advanced technology and insights from extensive RWD, we are reshaping drug discovery and development.”

These partnerships demonstrate OMNY Health’s commitment to AI-enabled healthcare improvement through acceleration of diverse participation in clinical trials and the support of research programs that aim to save lives and improve patient outcomes. To learn more about how OMNY Health is transforming lives and driving patient care by connecting providers and life sciences companies through data, visit https://omnyhealth.com/.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post OMNY Health unveils Data Platform for AI-Driven Health Tech Companies first appeared on AI-Tech Park.

K Health, the leading AI Primary Care platform, announced today that it has raised $50M in funding led by Claure Group, with participation from investors including Pablo Legorreta (founder and CEO of Royalty Pharma), and existing investors Mangrove Capital Partners, Valor Equity Partners, and Atreides Management, LP.

Primary care is a critical part of the US healthcare system, essential for improving clinical outcomes and reducing costs, with over a billion visits annually to primary and urgent care facilities. However, a burned-out physician supply and fragmentation from point solutions make access to high-quality longitudinal care out of reach for most people. Most technology solutions today have been applied on the edges of care to reduce administrative burden. Despite the immense potential of AI, these solutions have so far been unable to address the underlying problem of providing high-quality, truly personalized care at scale.

K Health is the only company that has developed peer-reviewed, clinical-grade AI for primary care. K’s co-pilot transforms the primary care visit. Instead of doctors taking patients through lengthy investigations and manually piecing together medical history from EMRs, K’s clinical-grade AI co-pilot takes patients through a personalized chat, grounds the assessment in relevant EMRs, and delivers to the providers the perfect medical chart with patient insights so they can make individualized diagnoses and treatments. This frees up the providers to truly engage with their patients, exercise clinical judgment and put in place a comprehensive follow-up care program. This new model of care delivery using K’s co-pilot achieves dramatically higher quality of care at lower costs vs traditional primary care.

Together with leading health systems, K Health has also been developing a comprehensive longitudinal care program that integrates virtual care with brick-and-mortar to create scalable access to primary care. This integrated care delivery model combines K’s primary care co-pilot, patients’ EMRs, and brick-and-mortar assets of the health system to navigate patients within a system, including diagnostic tests and specialty care. K has moved beyond a vision to scaled application – rebuilding the primary care model that has already helped health systems create a 15% increase to primary care access.

“K Health solves the need to make primary care visits highly personalized by giving doctors AI super powers that enable them to practice at the top of their license. Our primary care platform offers a concierge medical experience, with an assigned provider and 24/7 access to care. When partnered with leading health systems like Cedars-Sinai, this model creates significant benefits to access, clinical outcomes, and patient experience. All you need to get care is your health insurance, a stark contrast to concierge medicine services that typically cost thousands of dollars,” said Allon Bloch, founder and CEO of K Health.

The company has been developing AI technology for over seven years and employs proprietary data sets to highly personalize clinical care for patients.

“As I invest in the AI landscape, I have found it incredibly difficult to discover companies making tangible, real-world progress with AI,” Marcelo Claure, Founder and CEO of Claure Group, said. “K Health is the first company I’ve seen successfully using AI to impact millions of lives. They are addressing some of healthcare’s greatest challenges by providing accessibility to faster, higher-quality, lower cost care on a large scale.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post K Health Raises $50 Million Equity Funding Round first appeared on AI-Tech Park.

N-Power Medicine, a company reinventing the clinical trial process, announced the initial close of a Series B funding round, raising its total funding to date to $72 Million. The Series B round is led by Merck Global Health Innovation Fund, with participation by a US-based healthcare focused investor. The funds will support the expansion of the company’s network of oncology clinics and biopharmaceutical company collaborations leveraging N-Power’s unique platform for integrating clinical research into everyday patient care.

“The average oncology drug takes 10 years to go from development to market, and eight of those years are typically spent in clinical trials. Today’s clinical trial paradigm is very inefficient at the centers that run trials and out of reach for the majority of oncologists and their patients in the community,” said Mark Lee, M.D., Ph.D, N-Power Co-Founder and Chief Executive Officer. “Our vision is to radically accelerate drug development timelines through a new model where every oncologist and cancer patient can readily participate in advancing drug development. In the end we believe this is what patients will benefit from most.”

N-Power Medicine was founded in 2021 to accelerate the drug development process and expedite patients’ access to innovative therapies. The company has developed a first-of-its-kind integrated platform providing a single workflow for both clinical trial and routine patient management. N-Power’s “human in the loop” model, consisting of virtual and on-site staff assisted by AI-enabled workflow automation, supports oncologists in generating research-ready data for all patients in the practice and in preparing standardized clinical documentation for the medical record.

“At the Merck Global Health Innovation Fund we are focused on partnering with innovative companies such as N-Power that facilitate and optimize biopharmaceutical operations with the goal of improving patient care,” said David M. Rubin, Ph.D., Managing Director, Merck Global Health Innovation Fund. “N-Power’s unique approach offers the important opportunity to expand clinical research to more oncologists and their patients through standardized data collection, actionable insights, and the time and resources to participate in a model of accelerated drug development.”

N-Power’s platform consists of three fundamental components:

• The Kaleido Registry collects prospective, real-time, standardized patient data expressly designed to support clinical trials and drug development. To date, over 7,000 patients have consented and enrolled in the registry.
• The point of care technology enables seamless workflow management and provides secure, timely access to patient data and insights while ensuring compliance with regulatory requirements and quality standards for prospective clinical research.
• On-site and virtual experts support oncologists and research staff to operationalize the Registry and support clinical documentation, while reducing their overall workload, allowing them to focus on patient care and research.

With all patients participating in the Registry, standardized data collection readily enables actionable insights for clinical research, such as real-time, proactive identification of trial-eligible patients as well as patient characteristics and outcomes which inform trial design.

By partnering with oncologists, research staff, and patients to unlock the full potential of every patient’s data, N-Power Medicine is expanding access to clinical trials and enabling unprecedented insights for biopharmaceutical drug development.

“N-Power is working to solve major challenges for oncologists: managing electronic medical records, finding patients for clinical trials, and reporting requirements for CMS,” said Barbara L. McAneny, MD, FASCO, MACP, founder and Chief Executive Officer of the New Mexico Cancer Center in Albuquerque and Gallup and Past President of the American Medical Association. “Using N-Power’s ‘superscribes’ enables cancer doctors to focus more on patients, as the N-Power Staff manages the chart and consents the patient to join the registry. The registry allows us to find the trial candidates and send the required reports. The collaboration has been valuable.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post N-Power Medicine Emerges with Series B Funding first appeared on AI-Tech Park.